{"url_path":"/sec/nams/8-k/2026-06-03/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1936258/0001193125-26-254615-index.html","accession_number":"0001193125-26-254615","cik":"0001936258","ticker":"NAMS","issuer_name":"NewAmsterdam Pharma Co N.V.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1936258/0001193125-26-254615-index.html","primary_entity_key":"0001936258","primary_entity_name":"NewAmsterdam Pharma Co N.V."},"word_count":498,"has_tables":true,"body_markdown":"Item 5.07. Submission of Matters to a Vote of Security Holders.\n\n \n\nOn June 2, 2026, the Company held the Annual General Meeting. A total of 116,903,979 of the Company’s ordinary shares were eligible to vote as of the record date of May 7, 2025. A quorum of 91,538,612 ordinary shares, or approximately 78.3%, voted in person or by proxy at the Annual General Meeting.\n\n \n\nThe final results of each of the agenda items submitted to a vote of the shareholders are as follows:\n\n \n\nProposal 1. The Company’s shareholders approved the adoption of the Dutch statutory annual accounts for fiscal year ended December 31, 2025. The votes cast were as follows:\n\n \n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n91,484,326\n\n3,855\n\n50,431\n\n— \n\n \n\nProposal 2. The Company’s shareholders approved the discharge from liability for the Company’s directors with respect to the performance of their duties during the fiscal year ended December 31, 2025. The votes cast were as follows:\n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n85,229,605\n\n1,105,840\n\n51,557\n\n5,151,610\n\n \n\nProposal 3. The Company’s shareholders approved the instruction to Deloitte Accounts B.V. as the external auditor of the Company’s Dutch statutory annual accounts and Dutch statutory board report (including, to the extent applicable, sustainability reporting) for the fiscal year ending December 31, 2026. The votes cast were as follows:\n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n91,502,529\n\n4,636\n\n31,447\n\n— \n\n \n\n \n\n \n\n \n\n \n\n \n\nProposal 4. The Company’s shareholders ratified the selection by the Company’s Audit Committee of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. The votes cast were as follows:\n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n91,502,639\n\n4,618\n\n31,355\n\n— \n\n \n\nProposal 5. The Company’s shareholders approved the re-appointment of each of the two nominees listed below as a non-executive director of the Company, each to serve until the annual general meeting of shareholders in 2030, or until their earlier death, resignation or removal. The votes cast were as follows:\n\nName\n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\nJohn W. Smither\n\n85,375,639\n\n956,620\n\n54,743\n\n5,151,610\n\nJanneke van der Kamp\n\n75,256,863\n\n9,899,189\n\n1,230,950\n\n5,151,610\n\n \n\nProposal 6. The Company’s shareholders approved the extension of authorization for the Board of Directors to issue Ordinary Shares (or rights to subscribe for Ordinary Shares) in the Company’s capital, for a five-year period ending June 2, 2031. The votes cast were as follows:\n\n \n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n59,539,558\n\n26,801,646\n\n45,798\n\n5,151,610\n\n \n\nProposal 7. The Company’s shareholders approved the extension of authorization for the Board of Directors to limit or exclude pre-emption rights, for a five-year period ending June 2, 2031. The votes cast were as follows:\n\n \n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n57,890,766\n\n28,450,917\n\n45,319\n\n5,151,610\n\n \n\nProposal 8. The Company’s shareholders approved the ESPP. The votes cast were as follows:\n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n86,221,442\n\n139,927\n\n25,633\n\n5,151,610\n\n \n\nProposal 9. The Company’s shareholders approved the 2025 compensation of the Company’s named executive officers by a non-binding, advisory (“Say-on-Pay”) vote. The votes cast were as follows:\n\n \n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n81,100,259\n\n4,946,963\n\n339,780\n\n5,151,610"}